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Nuclear distributionClaudin-2 is expressed in human lung adenocarcinoma tissue and cell lines, although it is absent in normal lung
tissue. However, the role of claudin-2 in cell proliferation and the regulatory mechanism of intracellular
distribution remain undeﬁned. Proliferation of human adenocarcinoma A549 cells was decreased by claudin-2
knockdown together with a decrease in the percentage of S phase cells. This knockdown decreased the
expression levels of ZONAB and cell cycle regulators. Claudin-2 was distributed in the nucleus in human
adenocarcinoma tissues and proliferating A549 cells. The nuclear distribution of ZONAB and percentage of S
phase cells were higher in cells exogenously expressing claudin-2 with a nuclear localization signal than in
cells expressing claudin-2 with a nuclear export signal. Nuclear claudin-2 formed a complex with ZO-1,
ZONAB, and cyclin D1. Nuclear distribution of S208A mutant, a dephosphorylated form of claudin-2, was higher
than that of wild type. We suggest that nuclear distribution of claudin-2 is up-regulated by dephosphorylation
and claudin-2 serves to retain ZONAB and cyclin D1 in the nucleus, resulting in the enhancement of cell
proliferation in lung adenocarcinoma cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is one of the leading causes of cancer-related deaths,
and its incidence is increasing all over the world. Non-small cell lung
cancer (NSCLC) comprises over 80% of lung cancers diagnosed and has
poor survival with a 5-year survival rate of 15% [1]. The long-term sur-
vival rate of patients with NSCLC remains unsatisfactory due to an un-
clear pathological mechanism. NSCLC includes two major histological
subtypes: lung adenocarcinomas and squamous cell carcinomas. Ade-
nocarcinomas are the most common type in the United States and
Asia [2]. Tumor cells have the basic characteristics of unlimited prolifer-
ation, invasion, andmetastasis. Cell–cell adhesion is important in main-
taining epithelial morphology, cell proliferation, and migration [3].
At the apical pole of the intercellular junction of the lateral mem-
brane, epithelial cells form the tight junctions (TJs), which compose a
large complex of proteins including integralmembrane proteins and cy-
toplasmic plaque proteins [4]. The TJs separate apical and basolateral
epithelial compartments and limit the free diffusion of solutes acrossding protein; NSCLC, non-small
ochemistry, Department of
sity, 1-25-4 Daigaku-nishi, Gifuthese compartments. Furthermore, some tight junctional proteins
were shown to be involved in the regulation of cell proliferation [5,6].
Claudins and occludin are tetraspanning proteins that extend their ex-
tracellular loops across neighboring cells. The carboxy terminus of
most claudins has a PDZ-binding motif that can interact with the PDZ
domains of scaffolding proteins including zonula occludens (ZO)-1, -2,
and -3 [7]. Claudins comprise a large family of 27 members that form
homo- and heterotypic associations with each other [8,9]. Different
combinations of claudins can confer different properties to epithelial
cells in terms of physiological and pathophysiological functions.
Several claudins have been reported to exhibit abnormal expression
in human cancers. For example, claudin-1 is down-regulated in breast
cancer [10], whereas it is up-regulated in colon carcinoma [11] andmel-
anoma [12]. Claudin-4 is up-regulated in pancreas [13] and biliary tract
[14] cancers. Normal lung epithelia express claudin-1, -3, -4, -5, -7, and -
18 [15,16]. In contrast, the expression of claudin-2 is high in adenocar-
cinomas [17]. Claudin-2 expression may be useful in a differential diag-
nosis and as a target of chemotherapy against lung adenocarcinoma.
Recently, we revealed that claudin-2 is up-regulated by activation of a
MEK/ERK/c-Fos pathway in human lung adenocarcinoma A549 cells
[17]. However, the pathophysiological function of claudin-2 has not
been fully elucidated in A549 cells.
ZO-1 associated nucleic acid binding protein (ZONAB) is a Y-box
transcription factor that suppresses cell proliferationmediated by its in-
teraction with the SH3 domain of ZO-1 in highly conﬂuent epithelial
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regulates the expression of cell cycle regulators such as cyclin D1 and
proliferating cell nuclear antigen in proliferating cells. ZONAB is
overexpressed in several cancer tissues including the liver [19], pancre-
as [20], and colon [21]. The nuclear accumulation of ZONAB may be in-
volved in the abnormal proliferation of cancer cells.
In the present study, we found that claudin-2 is distributed in the
nucleus of human lung adenocarcinoma tissue and in both the nucleus
and TJs of proliferating A549 cells. The introduction of claudin-2 siRNA
decreased nuclear levels of ZONAB and cell cycle regulators, resulting
in the suppression of G1/S cell cycle progression. The exogenous expres-
sion of claudin-2 with nuclear localization signal increased nuclear
ZONAB levels and G1/S cell cycle progression in the endogenous
claudin-2 knockdown cells. Claudin-2 formed a complex with ZO-1,
ZONAB, and cyclin D1 in the nucleus. Nuclear distribution of claudin-2
was increased by dephosphorylation of Ser208. Our results indicate
that claudin-2 may be abnormally distributed in the nucleus mediated
by its dephosphorylation and enhances cell proliferation in lung
adenocarcinoma.
2. Materials and methods
2.1. Materials
Rabbit anti-claudin-1, claudin-2, and ZO-1, goat anti-occludin, and
mouse anti-claudin-2, and ZO-1 antibodies were obtained from
Zymed Laboratories (South San Francisco, CA, USA). Unless otherwise
indicated, rabbit anti-claudin-2 and mouse anti-ZO-1 antibodies were
used in immunoblotting and immunoﬂuorescence staining. Mouse
anti-E-cadherin and nucleoporin p62 antibodies were from Becton
Dickinson Biosciences (San Jose, CA, USA), rabbit anti-cyclin E1, mouse
anti-Na+/K+-ATPase α subunit, and goat anti-β-actin antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), mouse anti-
cyclin D1 antibody was from Lab Vision (Fremont, CA, USA), rabbit
anti-ZONAB antibody was from Upstate Cell Signaling Solutions (Lake
Placid, NY, USA), and rabbit anti-Rb and phosphorylated Rb (phos-
phor-Ser795) antibodies were from Signalway antibody (College Park,
MD, USA). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA,
USA). 4′,6-Diamidino-2-phenylindole (DAPI) and 3,8-diamino-5-[3-
(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide
(PI) were from Dojindo laboratories (Kumamoto, Japan). All other re-
agents were of the highest grade of purity available.
2.2. Plasmid constructs
Human claudin-2 cDNA was ampliﬁed by RT-PCR and subcloned
into the vector pCMV-Tag2, containing the FLAG epitope (BD Biosci-
ences Clontech, Mountain view, CA, USA). The oligonucleotides
encoding the nuclear localization signal (NLS) or nuclear export signal
(NES) were fused to the amino-terminus of FLAG-claudin-2. The
primers used to generate NLS-claudin-2 and NES-claudin-2 are listed
in Supplementary Table 1. PCR products were digested by both Nhe I
and Sal I, and were then cloned into the pTRE2/hyg vector (BD Biosci-
ences Clontech). The S208A mutant of claudin-2 was generated using
QuickChange II site-directed mutagenesis kit (Agilent Technologies,
Santa Clara, CA, USA). Sequence analysis was consigned to Bio Matrix
Research (Chiba, Japan).
2.3. Cell culture and transfection
The human lung adenocarcinoma A549 cell line was obtained from
the RIKEN BRC through the National Bio-Resource Project of the
MEXT, Japan. Cells were grown in Dulbecco's modiﬁed Eagle's medium
(Sigma-Aldrich, Saint Louis, MO, USA) supplemented with 5% fetal calf
serum (HyClone, Logan, UT, USA), 0.07 mg/ml penicillin-G potassium,
and 0.14 mg/ml streptomycin sulfate in a 5% CO2 atmosphere at 37 °C.Cells were transiently transfected with wild type claudin-2/pCMV-
Tag2, S208A claudin-2/pCMV-Tag2, NLS-claudin-2/pTRE2, or NEL-
claudin-2/pTRE2 vector using Lipofectamine 2000. Cells stably express-
ing the claudin-2/pSingle-tTS-shRNA vector were cultured in the pres-
ence of 1 μg/ml doxycycline for the inducible knockdown of
endogenous claudin-2 expression [22]. Cell growth was assessed by
counting the number of viable cells using a Neubauer chamber.
2.4. RNA isolation and RT-PCR
Total RNAwas isolated fromA549 cells using TRI reagent (Sigma-Al-
drich). Reverse transcription was carried out withM-MLV reverse tran-
scriptase (Promega, Madison, WI, USA) and random primers. Single
strand cDNA was ampliﬁed by PCR using GoTaq DNA polymerase
under the following conditions: denaturation at 94 °C for 0.5 min, an-
nealing at 54 °C for 0.5 min, and extension at 72 °C for 0.5 min; these
steps were repeated for 30 cycles. The primers used to PCR are listed
in Supplementary Table 1. Quantitative real time PCR was performed
using FastStart Universal SYBRGreenMaster (Roche Diagnostics,Mann-
heim, Germany). The threshold cycle (ct) for each PCR product was cal-
culated with the instrument's software, and ct values obtained for
claudin-1, claudin-2, E-cadherin, and ZO-1 were normalized by
subtracting the ct values obtained for β-actin. The resulting Δct values
were then used to calculate the relative change in mRNA expression
as a ratio (R) according to the equation R = 2−(Δct(each time) − Δct(24 h)).
2.5. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting
The preparation of cell lysateswas performed as described previous-
ly [22]. Nuclear and cytoplasmic extracts were prepared using NE-PER
nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) according to the manufacturer's instructions. Sam-
ples were applied to SDS-PAGE and blotted onto a PVDF membrane.
Phos-tag SDS-PAGE was used to analyze phosphorylation states of
claudin-2. The membrane was then incubated with each primary anti-
body (1:1000 dilution) at 4 °C for 16 h, followed by a peroxidase-
conjugated secondary antibody (1:5000 dilution) at room temperature
for 1 h. Finally, the blots were incubated in Pierce immunoblotting Sub-
strate (Thermo Fisher Scientiﬁc) and exposed to ﬁlm, or incubated in
ECL Prime Western Blotting Detection System (GE healthcare UK Ltd.,
Buckinghamshire, England) and scanned with a C-DiGit Blot Scanner
(LI-COR Biotechnology, Lincoln, NE, USA). Band density was quantiﬁed
with Doc-It LS image analysis software (UVP, Upland, CA, USA).
2.6. Immunoprecipitation
Cells were lysed in a immunoprecipitation buffer containing 150
mM NaCl, 0.5 mM EDTA, 0.5% Triton X-100, 50 mM Tris–HCl
(pH 7.4), a protease inhibitor cocktail (Sigma-Aldrich), and 1 mM
phenylmethylsulfonyl ﬂuoride. Cell lysates were incubated with anti-
claudin-2 or ZONAB antibody and Protein G-sepharose (GE Healthcare
UK Ltd.) or ExactaCruz (Santa Cruz Biotechnology) for 16 h at 4 °C
with gentle rocking. A negative control was immunoprecipitated with
rabbit IgG. After centrifugation at 6,000 ×g for 1 min, the pellet was
washed three times with the immunoprecipitation buffer. The immune
pellets were solubilized in a sample buffer for SDS-PAGE.
2.7. Immunoﬂuorescence staining
Lung tumor tissue array was obtained from BioChain Institute
(Newark, CA, USA). Tissue was ﬁxed in formalin followed by embedded
in parafﬁn. Tissue arrays are 6 μm in thickness andmounted on positively
charged glass slides followed by stained with H & E to ensure the qual-
ity. The slide includes 15 sections prepared from patients with lung ad-
enocarcinoma. After blockingwith 5% bovine serumalbumin for 1 h, the
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Fig. 1. Effect of the culture period on claudin-2 expression in A549 cells. (A) Representative
images of cells from the light microscope were acquired 24, 48, 72, and 96 h post-seeding.
Scale bar indicates 10 μm. (B) Left and right images show RT-PCR and immunoblotting,
respectively. Total RNA and cell lysates were prepared from A549 cells cultured for 24, 48,
72, and 96 h post-seeding. RT-PCR was performed using primers for human claudin-1,
claudin-2, E-cadherin, ZO-1, and β-actin. Cell lysates were immunoblotted with anti-
claudin-1, claudin-2, E-cadherin, ZO-1, and β-actin antibodies. (C) The expression levels
of mRNA were quantiﬁed by real-time PCR and were represented relative to values at
24 h. (D) The expression levels of protein were represented relative to values at
24 h. *P b 0.05 and **P b 0.01 signiﬁcantly different from 24 h. NS, P N 0.05. n = 3.
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(1:100) for 16 h at 4 °C. They were then incubated with Alexa Fluor
488 and Alexa Fluor 568-conjugated antibodies (1:100) including
DAPI for 1 h at room temperature. A549 cells were cultured on cover
glasses. Cells were ﬁxed with methanol for 10 min at −20 °C, then
permeabilized with 0.2% Triton X-100 for 15 min. After blocking with
2% Block Ace (Dainippon Sumitomo Pharma, Osaka, Japan) for 30 min,
cells were incubated with anti-claudin-1, claudin-2, E-cadherin, ZO-1,
or ZONAB antibody (1:100) for 16 h at 4 °C. They were then incubated
with Alexa Fluor 488 and Alexa Fluor 568-conjugated antibodies
(1:100) including DAPI for 1 h at room temperature. Immunolabeled
tissues and cells were visualized on an LSM 510 confocal microscope
(Carl Zeiss Microscopy GmbH, Göttingen, Germany).
2.8. Flow cytometry
After ﬁxationwith 70% ethanol, cells were incubatedwith 0.2 mg/ml
RNase at 37 °C for 30min. Cells were then incubatedwith 20 μg/ml PI at
room temperature for 30 min. Each sample was analyzed by a BD
FACSCant II Flow Cytometer (BD Biosciences) and the percentage of
cells in the G1, S, and G2/M phases of the cell cycle was analyzed.
2.9. Statistics
Results are presented as means ± S.E.M. Differences between
groups were analyzed with a one-way analysis of variance, and
corrections for multiple comparison were made using Tukey's multiple
comparison test. Comparisons between two groups were made using
the Student's t test. Signiﬁcant differences were assumed at P b 0.05.
3. Results
3.1. Effect of the culture period on claudin-2 expression
We examined the relationship between culture period and
change in the expression of junctional proteins in A549 adenocarci-
noma cells. A549 cells were cultured for 24, 48, 72, and 96 h, and
reached a conﬂuent state over 72 h (Fig. 1A). Claudin-2 mRNA levels
transiently increased at 48 h, and then returned to basal levels
(Fig. 1B and C). Similarly, its protein levels transiently increased at
48 and 72 h, and then returned to basal levels (Fig. 1B and D). In
contrast, protein levels of claudin-1 and ZO-1 were stable for 96 h.
The mRNA levels of E-cadherin increased at 72 and 96 h, while no
signiﬁcant change was observed in the protein levels. These results
indicate that the expression levels of claudin-2 increase in
proliferating cells.
3.2. Inhibition of cell proliferation by the knockdown of claudin-2
To examine the effect of claudin-2 expression on cell proliferation,
we established knockdown cells of claudin-2 using an inducible
shRNA vector [22]. Claudin-2 shRNA decreased claudin-2 protein levels
by 64.1% (n = 3). Cell numbers were counted 24, 48, and 72 h post-
seeding. Cell numbers were signiﬁcantly decreased by the knockdown
of claudin-2 at 48 and 72 h (Fig. 2A). Cell cycle progression affects cell
proliferation. Therefore, we examined the effect of knocking down
claudin-2 expression on cell cycle progression. The percentage of cells
in the S phase was signiﬁcantly decreased by claudin-2 knockdown,
whereas that in the G1 phase was increased (Fig. 2B). The percentage
of cells in G2/M was unchanged. The decrease in claudin-2 expression
by U0126, a MEK inhibitor, causes the decrease in the percentage of
cells in the S phase and increase in that in the G1 phase (Fig. S1).
These results suggest that claudin-2 expression affects cell cycle pro-
gression fromG1 to S phases. In the G1 to S phase transition, the activity
of cyclin-dependent kinases (CDKs) is positively regulated by cyclin D1
and E1 [23,24]. Rb is phosphorylated by complexes of cyclins and CDKs,leading to entry into S phase. The knockdown of cyclin D1 by siRNA is
reported to decrease cell proliferation in A549 cells [25]. The expression
levels of cyclin D1, cyclin E1, and phosphorylated Rb were signiﬁcantly
decreased by the knockdown of claudin-2 (Fig. 2C and D). These results
indicate that claudin-2 increases the expression of cell cycle regulators,
resulting in the acceleration of the G1–S transition.3.3. Decrease in the nuclear distribution of ZONAB by claudin-2 knockdown
Immunoﬂuorescence measurements showed that ZONAB is
distributed in both the nucleus and cytoplasm, whereas claudin-2
distributed in both the nucleus and cell–cell border area (Fig. 3A).
Claudin-2 knockdown decreased the red signal of claudin-2 and the nu-
clear green signal of ZONAB. Similarly, immunoblotting analysis
showed that the nuclear distribution of ZONAB is signiﬁcantly
decreased by claudin-2 knockdown (Fig. 3B and C). The cytoplasmic
distribution of ZONAB was increased by claudin-2 knockdown, but
this change was not signiﬁcant. These results indicate that claudin-2
increases the nuclear levels of ZONAB.
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To examine the effect of ZONAB expression on cell cycle progression,
we knocked down ZONAB expression using siRNA. ZONAB siRNA signif-
icantly decreased ZONAB protein levels by 59.6% (Fig. 4A and B). Similar
to the knockdown of claudin-2, the expression levels of cyclin D1, cyclin
E1, and phosphorylated Rb were decreased by ZONAB knockdown.
Furthermore, the percentage of cells in the S phase was signiﬁcantly
decreased by ZONAB knockdown, whereas that in the G1 phase was
increased (Fig. 4C). These results indicate that the decrease in ZONAB
expression affects the expression levels of cyclin D1, cyclin E1, and
phosphorylated Rb, resulting in the suppression of the G1–S transition.
3.5. Nuclear distribution of tight junctional protein claudin-2
The intracellular distribution of claudin-2 was examined by immu-
nocytochemistry. At 24 h post-seeding, claudin-2 was distributed in
the nucleus, cytoplasm, and cell–cell border area (Fig. 5A). The milder
detergent, digitonin, is able to selectively permeabilize the plasma
membrane. Claudin-2 was detected in the nucleus in Triton X-100-
permeabilized cells, whereas it was not detected in the nucleus in
digitonin-permeabilized cells (Fig. S2). These results suggest that
claudin-2 is not distributed in an outer nuclear membrane. ZO-1 and
E-cadherin were distributed in the nucleus, cytoplasm, and cell–cell
border area. Claudin-1 was mainly distributed in the cell–cell border
area and was partly distributed in the nucleus and cytoplasm. At 72 h
post-seeding, claudin-1 and E-cadherin were mainly distributed in the
cell–cell border area, whereas claudin-2 was distributed in both the nu-
cleus and cell–cell border area (Fig. 5B). Similar resultswere observed in
immunoblotting analysis using nuclear and cytoplasmic extracts
(Fig. 6). The isolation of nuclear and cytoplasmic fractions was checked
by nucleoporin p62, a nuclear protein, and Na+/K+-ATPase, a cytoplas-
mic protein, respectively. Expression levels of claudin-2 and ZO-1 in
both the nuclear and cytoplasmic fractions signiﬁcantly increased at
72 h, and then returned to basal levels. The distribution of claudin-2and ZO-1 in both the nucleus and cytosol was checked by another
mouse anti-claudin-2 and rabbit anti-ZO-1 antibodies (Fig. S3). Unlike
claudin-2, cytoplasmic claudin-1 levels increased in a time-dependent
manner and nuclear claudin-1 levels remained constant for 96 h.
These results indicate that claudin-2 and ZO-1 are distributed in both
the nucleus and TJs, and the expression levels of these proteins peaked
at 72 h in proliferating cells.3.6. Increase in claudin-2 expression in human lung adenocarcinoma tissue
We found that claudin-2 is distributed in both the nucleus and TJs of
A549 cells, but its distribution in human adenocarcinoma tissue remains
undeﬁned. Therefore, the localization of claudin-2 and ZO-1, a scaffold-
ing protein of the TJ, was examined using human lung tumor tissue
array. Claudin-2 protein was expressed in lung adenocarcinoma tissue
and was co-localized with ZO-1 in the nuclear area (Fig. 7). The nuclear
co-localization of claudin-2 and ZO-1 is similar to those in A549 cells.
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As shown in Fig. 2, claudin-2 knockdown decreased the percentage
of cells in the S phase, whereas it increased it in the G1 phase. Increased
claudin-2 expressionwas noted in the nucleus. However, it has not been
investigated whether cell cycle progression is regulated by nuclear
claudin-2. There is no report what sequence is involved in the nuclear
distribution of claudin-2.We searched classical NLS sequences usingnu-
clear localization software-based analysis (Nuclear Localization Signal
database, http://rostlab.org/services/nlsdb/). However, no classical NLS
sequences were detected in human claudin-2 sequence. Therefore, we
examined the effects of NLS- and NES-claudin-2 expression on cell
cycle progression. To avoid the effect of endogenous claudin-2, NLS-
and NES-claudin-2 were transfected into claudin-2 knockdown cells.
The exogenous expression of NLS- and NES-claudin-2 protein was con-
ﬁrmed by immunoblotting using FLAG and claudin-2 antibodies
(Fig. 8A). Single bandof claudin-2was detected in control cells, whereas
no band was detected inmock cells. The band of NLS- and NES-claudin-
2 was detected above endogenous claudin-2. Immunoﬂuorescence
measurements and immunoblotting analysis showed that NLS-
claudin-2 is distributed in the nucleus, whereas NES-claudin-2 was
mainly distributed in the cytoplasm (Fig. 8A and B). The nuclear
distribution of ZONAB was signiﬁcantly increased by the expression of
NLS-claudin-2 compared with that of NES-claudin-2 (Fig. 8C). Further-
more, the percentage of cells in the S phase and G1 phase were higher
and lower, respectively, with NLS-claudin-2 than with NES-claudin-2
(Fig. 8D). These results indicate that nuclear claudin-2 increases the
nuclear distribution of ZONAB, resulting in the acceleration of the
G1–S transition.3.8. Association of nuclear claudin-2 with ZONAB, ZO-1, and cyclin D1
Claudin-2, ZO-1, and ZONAB were distributed in the nucleus of pro-
liferating cells, and the ﬂuorescence pattern of claudin-2 was merged
with those of ZO-1 and ZONAB (Figs. 3 and 5). Therefore, these results
raised the possibility that claudin-2 is associated with ZO-1 and
ZONAB in the nucleus. In the immunoprecipitation assay, nuclear
claudin-2 was associated with ZO-1 and ZONAB (Fig. 9). Furthermore,
claudin-2 was associated with cyclin D1, but not with cyclin E. Theseresults indicate that claudin-2 forms a complex with ZO-1, ZONAB,
and cyclin D1 in the nucleus.3.9. Increase in nuclear claudin-2 level by dephosphorylation
Claudin-2 was distributed in both the nucleus and TJs in A549 cells,
but the underlyingmechanism is not fully understood. PDZ binding do-
main in the carboxyl-terminal tail of claudins is necessary for the distri-
bution in the TJs [26]. The ratio of nuclear claudin-2 in wild type was
similar to that in ΔPDZmutant (Fig. S4). In contrast, the ratio of nuclear
claudin-2 in Δcytosol mutant was signiﬁcantly lower than that in wild
type. These results indicate that claudin-2 may have NLS sequence in
the carboxyl-terminal cytosolic region and PDZ binding motif is not
NLS sequence. Claudin-2 has recently been reported to be constitutively
phosphorylated at S208 inmouse kidney and renal tubularMDCK II cells
[27]. We examined the effect of phosphorylation on the nuclear
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2084 A. Ikari et al. / Biochimica et Biophysica Acta 1843 (2014) 2079–2088distribution of claudin-2. In a phos-tag gel, the upper band of claudin-2
detected in control cells was disappeared by forskolin, indicating
forskolin dephosphorylates claudin-2 (Fig. 10). Forskolin increased
nuclear distribution of claudin-2 compared to control. S208A mutant,
a dephosphorylated form of claudin-2, was detected in lower band in
a phos-tag gel (Fig. 11) similar to those in the forskolin-treated cells.Claudin-2
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ZO-1
(mouse)
DAPI Merge
Claudin-2
(mouse)
ZO-1
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Fig. 7. Expression of claudin-2 in human lung adenocarcinoma tissue. The sections con-
taining lung adenocarcinoma tissues were stained with two types of anti-claudin-2 and
ZO-1 antibodies, and DAPI (blue). The arrowheads indicate the co-localization of
claudin-2 with ZO-1 in the nucleus. The scale bar represents 10 μm.The nuclear distribution of S208A was much more abundant than that
of wild type. The association of claudin-2 with ZO-1, ZONAB, and cyclin
D1 was increased by forskolin or mutation of S208A. These results
suggest that dephosphorylation of Ser208 is involved in the nuclear
distribution of claudin-2 and formation of the claudin-2 complex with
ZO-1, ZONAB, and cyclin D1 in the nucleus.
4. Discussion
We recently reported that mRNA levels of claudin-2 are muchmore
abundant in human lung adenocarcinoma tissue and adenocarcinoma
cell lines including A549, RERF-LC-MA, and PC-3 than in normal lung
tissue [17]. Similar to lung adenocarcinoma, claudin-2 expression is
higher in colonic [28], gastric [29], breast [30], and cervical [31] cancers.
In contrast, claudin-2 expression is down-regulated in breast carcinoma
[32] and prostate adenocarcinoma [33]. These reports suggest that the
increase in claudin-2 expressionmight be a consequence of carcinogen-
esis with organ speciﬁcity. Forced claudin-2 expression in colon cancer
cells increases tumor growth [28], but the role of claudin-2 in cell
proliferation has remained undeﬁned in lung adenocarcinoma. In the
present study, we showed that claudin-2 protein levels transiently in-
creased at 48 and 72 h under proliferating conditions, and then
returned to basal levels under resting conﬂuent conditions (Fig. 1).
Claudin-2 knockdown decreased the cell number and cell population
in the S phase concomitant with the decrease in cyclin D1, cyclin E1,
and phosphorylated Rb (Fig. 2). Claudin-2 may enhance cell
proliferation mediated by the acceleration of cell cycle G1–S transition
in A549 cells.
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sity [34]. A reduction in ZONAB in the nucleus is reported to reduce the
proliferation of renal epithelial cells [35].We found that ZONAB is highly
distributed in the nucleus in the claudin-2-expressing A549 cells
(Fig. 3). Claudin-2 knockdown decreased the nuclear distribution of
ZONAB. Furthermore, ZONAB siRNA decreased the cell population in
the S phase concomitant with the decrease in cyclin D1, cyclin E1, and
phosphorylated Rb (Fig. 4). These results were similar to those in
claudin-2 knockdown cells (Fig. 2). Claudin-2 may enhance cellIg
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The nuclear distribution of several cell junctional proteins including
ZO-1, ZO-2, and ZONAB is known to be correlatedwith oncogenic trans-
formation and cell proliferation [36,37]. It should be noted that both
claudin-2 and ZO-1 are distributed in the nucleus in human lung adeno-
carcinoma tissue (Fig. 7). Immunoﬂuorescence and immunoblotting
analyses showed that claudin-2 is distributed in the nucleus of A549
cells under proliferating conditions (Figs. 5 and 6). The distribution of
claudin-2 and ZO-1 in both the nucleus and cytosol was revealed by
two types of claudin-2 and ZO-1 antibodies. We suggest that nuclear
claudin-2 is involved in the up-regulation of cell proliferation in lung ad-
enocarcinoma. The nuclear distribution of claudin-1 has been reported
in several cancers. The pathophysiological function of nuclear claudin-
1 remains to be determined, but nuclear claudin-1 may be associated
with nuclear localization of β-catenin in colon cancer [11] and may re-
duce apoptosis of nasopharyngeal carcinoma cells under serum with-
drawal of ﬂuorouracil treatment [38]. Our results indicated that
claudin-1 is mainly distributed in the TJ and cytoplasmic fraction in
A549 cells. Furthermore, claudin-1 protein levels remained constant
under proliferating and resting conﬂuent conditions. We suggest that
nuclear claudin-2, but not claudin-1, plays key role in enhancing cell
proliferation in A549 cells.
Claudin-2 and ZO-1 were immunoprecipitated with ZONAB anti-
body (Fig. 9). In contrast, these proteins were not immunoprecipitated
with rabbit IgG. Similarly, ZO-1 and ZONAB were immunoprecipitated
with claudin-2 antibody. Cyclin D1 was immunoprecipitated with
claudin-2 or ZONAB antibody, while cyclin E was not. Our results sug-
gest that claudin-2 forms a complex with ZO-1, ZONAB, and cyclin D1
in the nucleus, resulting in the acceleration of cell cycle G1–S transition
in A549 cells. The overexpression of cyclin D1 has been frequently found
in NSCLC [39,40]. Cyclin D1 is phosphorylated by glycogen synthase
kinase-3β and exported from the nucleus. Following its nuclear export,
cyclin D1 is ubiquitinated by ubiquitin-ligases and degraded by the
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cyclin D1 may prevent the phosphorylation or nuclear export of cyclin
D1.
Claudin-2 knockdown decreased cell proliferation in A549 cells.
Does nuclear claudin-2 play a role in the regulation of cell growth? Un-
fortunately, we could not detect any classical NLS sequences using nu-
clear localization software-based analysis. Lange et al. [43] reported
that about 57% of steady-state nuclear proteins contain classical NLS,
whereas about 43% do not using a global yeast GFP screen. The nuclear
distribution of ZONAB and percentage of the S phase were higher with
NLS-claudin-2 than with NES-claudin-2, indicating that nuclear
claudin-2 is involved in the promotion of cell cycle progression. This is
the ﬁrst report to show that nuclear claudin-2 can function as a positive
regulator of cell proliferation.
Forskolin and prostaglandin E2 decrease the level of phosphorylated
claudin-2 in MDCK II cells [27]. They suggest that the increase in cAMP
may activate a protein phosphatase that dephosphorylates claudin-2
at S208. The cytoplasmic distribution of S208A mutant, a non-
phosphorylatable form of claudin-2, is much more abundant than that
of wild type. Phosphorylation of S208 may play a major role in the re-
tention of claudin-2 at the plasma membrane. Similar to the report in
MDCK II cells, claudin-2 was phosphorylated in A549 cells and forskolin
decreased the level of phosphorylated claudin-2 (Fig. 10). The nuclear
distribution of claudin-2 in forskolin-treated cells (Fig. 10) and S208A
mutant (Fig. 11) was much more abundant than that of claudin-2 in
control cells and wild type, respectively. We suggest that nuclear trans-
port or retention of claudin-2 is partially regulated by phosphorylation
at S208.
Taken together, claudin-2 was distributed in the nucleus and TJs in
human lung adenocarcinoma tissue and A549 cells. Claudin-2 knock-
down decreased the nuclear distribution of ZONAB and suppressed
cell cycle G1–S transition. Nuclear claudin-2 formed a complex with
ZO-1, ZONAB, and cyclin D1, and enhances cell proliferation.We suggest
that nuclear claudin-2 expression is involved in the progression of lung
adenocarcinoma. Nuclear claudin-2may be a novel target for the devel-
opment of anticancer agents.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.05.017.
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